 Every day, we see women in our clinic who are deciding whether to continue a selective serotonin reuptake inhibitor (SSRI) for management of depression or anxiety during pregnancy. As a class, SSRI use during [...]
 Last year France banned the use of the antiepileptic during valproate in certain populations of reproductive age women.  Now the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has banned the use of [...]
The following post was first published in OB/GYN News. Please see our OB/GYN News archives here. Publish date: April 23, 2018 The last two decades have seen an ever-growing number of reports on risks of fetal exposure to [...]
EURAP is an international registry for antiepileptic drugs and pregnancy. Â At its inception in 1999, it included only European countries but EURAP has grown and now includes 42 countries from Europe, Australia, Asia, South America. [...]
We have, over the last twenty years, seen many studies assessing the risks associated with prenatal exposure to antidepressants. Â For the serotonin reuptake inhibitors (SRIs), we have a fairly large body of data regarding the [...]
 There have long been concerns regarding the use of the anticonvulsant valproate (Depakote) during pregnancy.  First trimester use of valproate has been associated with a 3-5% risk of neural tube defects, as well as [...]
 Serotonin reuptake inhibitor (SRI) antidepressants may affect platelet aggregation and thus may increase the risk of bleeding.  Over the last few years, we have seen several studies which have sought to determine if exposure [...]
Analyzing data from the Swedish Medical Birth Register, the Prescribed Drug Register, and the Swedish Neonatal Quality Register, researchers compared infants exposed to ADHD medication during pregnancy with infants whose mothers never used these drugs [...]
Topiramate (TPM, marketed as Topamax) is an antiepileptic drug which is also used for migraine prophylaxis, weight loss, and, less commonly, as a mood stabilizer. Â Over the last few years we have seen several studies [...]
For women with mild to moderate attention-deficit/hyperactivity disorder (ADHD) symptoms, we often recommend discontinuing stimulant medications and switching to a non-pharmacologic intervention. Â Many women experience some decrease in their level of functioning; however, they are [...]
